This is the "Home" page of the "Grand Rounds 02/20/13 @ BID-Needham - Fadi Badlissi, MD" guide.
Alternate Page for Screenreader Users
Skip to Page Navigation
Skip to Page Content

Grand Rounds 02/20/13 @ BID-Needham - Fadi Badlissi, MD  

Last Updated: Aug 12, 2014 URL: http://bidmc.libguides.com/Badlissi Print Guide RSS Updates
Home Print Page
  Search: 
 

Speaker: Date: Topic

Fadi Badlissi, MD

Feb. 20, 2013

Gout, Outpatient and Inpatient Conundrum: Do We Complicate Matters More Than We Need To?

      

    Obtaining the Powerpoint Presentation

    Contact Lauren Oliva at loliva@bidneedham.org

        

      Responsibility for Content

      The main points and articles links were sent by the Medical Library and the CME Committee.

      Diane E. Young, Information Specialist; dyoung3@bidmc.harvard.edu

       

       

          

        Take-Away Points of the Lecture

        1.  Always combine the initiation of uric acid lowering agents with preventive Rx such as NSAIDs or colchicine.

        2.  Target uric acid < 6 mg/dl.

        3.  No need to reduce a stable dose of allopurinol for renal insufficiency as long as it is tolerated.

            

          Articles Cited in the Presentation

          1.  Khanna D et al: 2012 American College of Rheumatology guidelines for management of gout. Part 1: Systematic nonpharmacologic and pharmacologic therapeutic approaches to hyperuricemia. Arthritis Care Res 2012 Oct;64(10):1431-1446.

           

          2.  Khanna D et al: 2012 American College of Rheumatology guidelines for management of gout. Part 2: Therapy and anti-inflammatory prophylaxis of acute gouty arthritis. Arthritis Care Res 2012 Oct;64(10):1447-1461.    


          3.  Jordan KM et al: British Society for Rheumatology and British Health Professionals in Rheumatology guideline for the management of gout. Rheumatology (Oxford) 2007 Aug;46(8):1372-1374. 

           

          4.  Zhang W et al: EULAR evidence based recommendations for gout. Part 1: Diagnosis. Report of a task force of the Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT).  Ann Rheum Dis 2006 Oct; 65(10):1301-1311.

           

          5.  Zhang W et al: EULAR evidence based recommendations for gout. Part II: Management. Report of a task force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis 2006 Oct;65(10):1312-1324.

           

          6.  Choi HK et al: Pathogenesis of gout. Ann Intern Med 2005 Oct.4;143(7):499-516. 

           

          7.  Kramer HM & Curhan G: The association between gout and nephrolithiasis: the National Health and Nutrition Examination Survey III, 1988-1994. Am J Kidney Dis 2002 Jul;40(1):37-42.  SEE PDF ATTACHED AT END OF ARTICLE.

           

          8.  Arromdee E et al: Epidemiology of gout: is the incidence rising? J Rheumatol 2002 Nov;29(11):2403-2406

           

          9.  Lawrence RC et al: Estimates of the prevalence of arthritis and other rheumatic conditions in the United States. Part II. Arthritis Rheum 2008 Jan;58(1):26-35.

           

          10. Terkeltaub RA et al: High versus low dosing of oral colchicine for early acute gout flare: Twenty-four-hour outcome of the first multicenter, randomized, double-blind, placebo-controlled, parallel-group, dose-comparison colchicine study. Arthritis Rheum 2010 Apr;62(4):1060-1068.

          11. Sundy JS et al: Efficacy and tolerability of pegloticase for the treatment of chronic gout in patients refractory to conventional treatment: two randomized controlled trials. JAMA 2011 Aug 17;306(7):711-720

           

          .12. Becker MA et al: Long-term safety of pegloticase in chronic gout refractory to conventional treatment. Ann Rheum Dis 2012 Nov 10 [Epub ahead of print].

           

              

            Your Guide

            Profile Image
            Diane E. Young
            Contact Info
            Knowledge Services
            Beth Israel Deaconess Medical Center
            Boston, MA 02215
            Tel: 617-632-8312
            Send Email
             

            THIS SITE IS MAINTAINED BY KNOWLEDGE SERVICES AT THE BETH ISRAEL DEACONESS MEDICAL CENTER.
            CLICK HERE TO ASK A QUESTION OR REPORT A PROBLEM.

            Description

            Loading  Loading...

            Tip